Franklin Biotechnology Discv A(acc)SGD |
| Performance History | 30/06/2017 |
| Growth of 1,000 (ZAR) |
 | Fund | 102.6 | 48.9 | 40.5 | -27.3 | 9.2 |
| +/-Cat | 7.6 | 4.8 | -3.1 | 1.6 | -4.3 |
| +/-Idx | -4.4 | 4.4 | -3.7 | -4.9 | -1.1 |
| Category: Sector Equity Biotechnology | ||||||
| Category Benchmark: MSCI World/Biotechnology NR... | ||||||
| Key Stats | ||
| NAV 26/07/2017 | SGD 31.98 | |
| Day Change | 0.54% | |
| Morningstar Category™ | Sector Equity Biotechnology | |
| ISIN | LU0320765992 | |
| Fund Size (Mil) 30/06/2017 | USD 2408.64 | |
| Share Class Size (Mil) 30/06/2017 | SGD 26.03 | |
| Max Initial Charge | 5.75% | |
| Ongoing Charge 27/01/2017 | 1.83% | |
| Investment Objective: Franklin Biotechnology Discv A(acc)SGD |
| The Fund’s investment objective is capital appreciation. The Fund invests principally in equity securities of biotechnology companies and discovery research firms (including small to mid-sized companies) located in the US and other countries, and to a lesser extent in debt securities of any type of issuers worldwide. |
| Returns | |||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Steven Kornfeld 15/09/2015 | ||
Inception Date 25/10/2007 | ||
| Advertisement |
| Category Benchmark | |
| Fund Benchmark | Morningstar Benchmark |
| NASDAQ Biotechnology PR USD | MSCI World/Biotechnology NR USD |
| Portfolio Profile for Franklin Biotechnology Discv A(acc)SGD | 30/06/2017 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Celgene Corp |  Healthcare | 9.69 |
 Alexion Pharmaceuticals Inc | Healthcare | 7.67 |
| Incyte Corp | Healthcare | 5.88 |
| Regeneron Pharmaceuticals Inc | Healthcare | 5.56 |
| Biogen Inc | Healthcare | 4.75 |
 | ||
Increase Decrease  New since last portfolio | ||
| Franklin Biotechnology Discv A(acc)SGD | ||
